1
|
Chen W: Cancer statistics: Updated cancer
burden in China. Chin J Cancer Res. 27:12015. View Article : Google Scholar : PubMed/NCBI
|
2
|
Tao Q and Chan AT: Nasopharyngeal
carcinoma: Molecular pathogenesis and therapeutic developments.
Expert Rev Mol Med. 9:1–24. 2007. View Article : Google Scholar : PubMed/NCBI
|
3
|
Rottey S, Madani I, Deron P and Van Belle
S: Modern treatment for nasopharyngeal carcinoma: Current status
and prospects. Curr Opin Oncol. 23:254–258. 2011. View Article : Google Scholar : PubMed/NCBI
|
4
|
Jia WH, Huang QH, Liao J, Ye W, Shugart
YY, Liu Q, Chen LZ, Li YH, Lin X, Wen FL, et al: Trends in
incidence and mortality of nasopharyngeal carcinoma over a 20–25
year period (1978/1983-2002) in Sihui and Cangwu counties in
southern China. BMC Cancer. 6:1782006. View Article : Google Scholar : PubMed/NCBI
|
5
|
Lai SZ, Li WF, Chen L, Luo W, Chen YY, Liu
LZ, Sun Y, Lin AH, Liu MZ and Ma J: How does intensity-modulated
radiotherapy versus conventional two-dimensional radiotherapy
influence the treatment results in nasopharyngeal carcinoma
patients? Int J Radiat Oncol Biol Phys. 80:661–668. 2011.
View Article : Google Scholar : PubMed/NCBI
|
6
|
Xiao WW, Huang SM, Han F, Wu SX, Lu LX,
Lin CG, Deng XW, Lu TX, Cui NJ and Zhao C: Local control, survival,
and late toxicities of locally advanced nasopharyngeal carcinoma
treated by simultaneous modulated accelerated radiotherapy combined
with cisplatin concurrent chemotherapy: Long-term results of a
phase 2 study. Cancer. 117:1874–1883. 2011. View Article : Google Scholar : PubMed/NCBI
|
7
|
Chen-Scarabelli C, Kaza AR and Scarabelli
T: Syncope due to nasopharyngeal carcinoma. Lancet Oncol.
6:347–349. 2005. View Article : Google Scholar : PubMed/NCBI
|
8
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
9
|
He L and Hannon GJ: MicroRNAs: Small RNAs
with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004.
View Article : Google Scholar : PubMed/NCBI
|
10
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
11
|
Ambros V: MicroRNA pathways in flies and
worms: Growth, death, fat, stress, and timing. Cell. 113:673–676.
2003. View Article : Google Scholar : PubMed/NCBI
|
12
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
13
|
Ma XP, Zhang T, Peng B, Yu L and Jiang de
K: Association between microRNA polymorphisms and cancer risk based
on the findings of 66 case-control studies. PLoS One. 8:e795842013.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Liu N, Jiang N, Guo R, Jiang W, He QM, Xu
YF, Li YQ, Tang LL, Mao YP, Sun Y and Ma J: miR-451 inhibits cell
growth and invasion by targeting MIF and is associated with
survival in nasopharyngeal carcinoma. Mol Cancer. 12:1232013.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Wu D, Zhou Y, Pan H, Zhou J, Fan Y and Qu
P: MicroRNA-99a inhibiting cell proliferation, migration and
invasion by targeting fibroblast growth factor receptor 3 in
bladder cancer. Oncol Lett. 7:1219–1224. 2014. View Article : Google Scholar : PubMed/NCBI
|
16
|
Wu D, Niu X, Pan H, Zhou Y, Qu P and Zhou
J: MicroRNA-335 is downregulated in bladder cancer and inhibits
cell growth, migration and invasion via targeting ROCK1. Mol Med
Rep. 13:4379–4385. 2016. View Article : Google Scholar : PubMed/NCBI
|
17
|
Fabbri M, Ivan M, Cimmino A, Negrini M and
Calin GA: Regulatory mechanisms of microRNAs involvement in cancer.
Expert Opin Biol Ther. 7:1009–1019. 2007. View Article : Google Scholar : PubMed/NCBI
|
18
|
Zhang B, Pan X, Cobb GP and Anderson TA:
microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12.
2007. View Article : Google Scholar : PubMed/NCBI
|
19
|
Liu P, Hu Y, Ma L, Du M, Xia L and Hu Z:
miR-425 inhibits melanoma metastasis through repression of PI3K-Akt
pathway by targeting IGF-1. Biomed Pharmacother. 75:51–57. 2015.
View Article : Google Scholar : PubMed/NCBI
|
20
|
Liu L, Zhao Z, Zhou W, Fan X, Zhan Q and
Song Y: Enhanced expression of miR-425 promotes esophageal squamous
cell carcinoma tumorigenesis by targeting SMAD2. J Genet Genomics.
42:601–611. 2015. View Article : Google Scholar : PubMed/NCBI
|
21
|
Cristóbal I, Madoz-Gúrpide J, Rojo F and
García-Foncillas J: Potential therapeutic value of miR-425-5p in
metastatic colorectal cancer. J Cell Mol Med. 20:2213–2214. 2016.
View Article : Google Scholar : PubMed/NCBI
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
23
|
Chen C, Lu Z, Yang J, Hao W, Qin Y, Wang
H, Xie C and Xie R: miR-17-5p promotes cancer cell proliferation
and tumorigenesis in nasopharyngeal carcinoma by targeting p21.
Cancer Med. 5:3489–3499. 2016. View
Article : Google Scholar : PubMed/NCBI
|
24
|
Sun KY, Peng T, Chen Z, Huang J and Zhou
XH: MicroRNA-1275 suppresses cell growth, and retards G1/S
transition in human nasopharyngeal carcinoma by down-regulation of
HOXB5. J Cell Commun Signal. 10:305–314. 2016. View Article : Google Scholar : PubMed/NCBI
|
25
|
Zhu K, He Y, Xia C, Yan J, Hou J, Kong D,
Yang Y and Zheng G: MicroRNA-15a inhibits proliferation and induces
apoptosis in CNE1 nasopharyngeal carcinoma cells. Oncol Res.
24:145–151. 2016. View Article : Google Scholar : PubMed/NCBI
|
26
|
Zhang Z, Li Y, Fan L, Zhao Q, Tan B, Li Z
and Zang A: microRNA-425-5p is upregulated in human gastric cancer
and contributes to invasion and metastasis in vitro and in vivo.
Exp Ther Med. 9:1617–1622. 2015. View Article : Google Scholar : PubMed/NCBI
|
27
|
Sun L, Jiang R, Li J, Wang B, Ma C, Lv Y
and Mu N: MicoRNA-425-5p is a potential prognostic biomarker for
cervical cancer. Ann Clin Biochem. 54:127–133. 2017. View Article : Google Scholar : PubMed/NCBI
|
28
|
Liu J, Li T, Zhang N, Yang X, Wang Z, Ma
J, Gu X, Fan Y and Cai D: MiR-425 up-regulation induced by
interleukin-1beta promotes the proliferation of gastric cancer cell
AGS. Zhonghua Yi Xue Za Zhi. 94:1889–1893. 2014.(In Chinese).
PubMed/NCBI
|
29
|
Bao C, Wang J, Ma W, Wang X and Cheng Y:
HDGF: A novel jack-of-all-trades in cancer. Future Oncol.
10:2675–2685. 2014. View Article : Google Scholar : PubMed/NCBI
|
30
|
Huang JS, Chao CC, Su TL, Yeh SH, Chen DS,
Chen CT, Chen PJ and Jou YS: Diverse cellular transformation
capability of overexpressed genes in human hepatocellular
carcinoma. Biochem Biophys Res Commun. 315:950–958. 2004.
View Article : Google Scholar : PubMed/NCBI
|
31
|
Zhang J, Qi J, Guo Y, Guo Y, Fu W, Zhou B,
Wu G, Han L and He A: Aberrant expression of HDGF and its
prognostic values in surgically resected non-small cell lung
cancer. Zhongguo Fei Ai Za Zhi. 14:211–218. 2011.PubMed/NCBI
|
32
|
Yamamoto S, Tomita Y, Hoshida Y, Takiguchi
S, Fujiwara Y, Yasuda T, Doki Y, Yoshida K, Aozasa K, Nakamura H
and Monden M: Expression of hepatoma-derived growth factor is
correlated with lymph node metastasis and prognosis of gastric
carcinoma. Clin Cancer Res. 12:117–122. 2006. View Article : Google Scholar : PubMed/NCBI
|
33
|
Tsai CC, Huang SC, Tai MH, Chien CC, Huang
CC and Hsu YC: Hepatoma-derived growth factor upregulation is
correlated with prognostic factors of early-stage cervical
adenocarcinoma. Int J Mol Sci. 15:21492–21504. 2014. View Article : Google Scholar : PubMed/NCBI
|
34
|
Guo Z, He Y, Wang S, Zhang A, Zhao P, Gao
C and Cao B: Various effects of hepatoma-derived growth factor on
cell growth, migration and invasion of breast cancer and prostate
cancer cells. Oncol Rep. 26:511–517. 2011.PubMed/NCBI
|
35
|
Li SZ, Zhao YB, Cao WD, Qu Y, Luo P, Zhen
HN, Chen XY, Yan ZF and Fei Z: The expression of hepatoma-derived
growth factor in primary central nervous system lymphoma and its
correlation with angiogenesis, proliferation and clinical outcome.
Med Oncol. 30:6222013. View Article : Google Scholar : PubMed/NCBI
|
36
|
Enomoto H, Nakamura H, Liu W, Iwata Y,
Nishikawa H, Takata R, Yoh K, Hasegawa K, Ishii A, Takashima T, et
al: Down-regulation of HDGF inhibits the growth of hepatocellular
carcinoma cells in vitro and in vivo. Anticancer Res. 35:6475–6479.
2015.PubMed/NCBI
|
37
|
Wang S and Fang W: Increased expression of
hepatoma-derived growth factor correlates with poor prognosis in
human nasopharyngeal carcinoma. Histopathology. 58:217–224. 2011.
View Article : Google Scholar : PubMed/NCBI
|